Calamos Advisors LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.5% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 563,184 shares of the biopharmaceutical company’s stock after purchasing an additional 2,912 shares during the period. Calamos Advisors LLC’s holdings in Gilead Sciences were worth $36,613,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of GILD. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp raised its holdings in shares of Gilead Sciences by 95.7% during the fourth quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 554,083 shares of the biopharmaceutical company’s stock valued at $34,658,000 after acquiring an additional 271,000 shares during the period. Chilton Capital Management LLC raised its holdings in shares of Gilead Sciences by 3.5% during the fourth quarter. Chilton Capital Management LLC now owns 16,468 shares of the biopharmaceutical company’s stock valued at $1,030,000 after acquiring an additional 555 shares during the period. Sectoral Asset Management Inc raised its holdings in shares of Gilead Sciences by 59.6% during the fourth quarter. Sectoral Asset Management Inc now owns 424,890 shares of the biopharmaceutical company’s stock valued at $26,577,000 after acquiring an additional 158,750 shares during the period. Nicholas Company Inc. raised its holdings in shares of Gilead Sciences by 2.7% during the fourth quarter. Nicholas Company Inc. now owns 506,760 shares of the biopharmaceutical company’s stock valued at $31,697,000 after acquiring an additional 13,500 shares during the period. Finally, AIMZ Investment Advisors LLC raised its holdings in shares of Gilead Sciences by 39.9% during the fourth quarter. AIMZ Investment Advisors LLC now owns 53,738 shares of the biopharmaceutical company’s stock valued at $3,361,000 after acquiring an additional 15,333 shares during the period. 80.19% of the stock is owned by institutional investors.

In other news, Director Gayle E. Wilson sold 19,068 shares of the stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $67.08, for a total transaction of $1,279,081.44. Following the transaction, the director now owns 143,567 shares in the company, valued at approximately $9,630,474.36. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director John Francis Cogan sold 2,700 shares of the stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $65.07, for a total transaction of $175,689.00. Following the transaction, the director now owns 57,560 shares in the company, valued at approximately $3,745,429.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 39,402 shares of company stock worth $2,613,954. 0.20% of the stock is currently owned by company insiders.

A number of equities research analysts have recently issued reports on the stock. Mizuho set a $88.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Friday. UBS Group upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating and boosted their price target for the company from $75.00 to $77.00 in a report on Wednesday, April 10th. Zacks Investment Research upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, April 9th. Maxim Group reiterated a “buy” rating and issued a $84.00 price objective on shares of Gilead Sciences in a research note on Friday, March 29th. Finally, Oppenheimer set a $85.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Tuesday, March 19th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $82.00.

Gilead Sciences stock opened at $65.43 on Tuesday. The company has a market capitalization of $84.58 billion, a price-to-earnings ratio of 10.64, a P/E/G ratio of 4.17 and a beta of 1.16. The company has a current ratio of 3.38, a quick ratio of 3.30 and a debt-to-equity ratio of 1.19. Gilead Sciences, Inc. has a twelve month low of $60.32 and a twelve month high of $79.61.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.70 by ($0.26). Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same quarter last year, the company earned $1.78 EPS. The business’s revenue for the quarter was down 2.6% compared to the same quarter last year. Equities research analysts forecast that Gilead Sciences, Inc. will post 6.23 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were paid a dividend of $0.63 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.57. The ex-dividend date was Thursday, March 14th. This represents a $2.52 annualized dividend and a dividend yield of 3.85%. Gilead Sciences’s dividend payout ratio is 40.98%.

COPYRIGHT VIOLATION WARNING: “Calamos Advisors LLC Has $36.61 Million Holdings in Gilead Sciences, Inc. (GILD)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2019/04/16/calamos-advisors-llc-has-36-61-million-holdings-in-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Featured Article: What is a trade deficit?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.